secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001711279-23-000067
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech reports Q2 2023 net loss $33.2M; VYJUVEK launch yields 121 patient start forms
--------------------------------------------------------------------------------

- VYJUVEK approved May 19; 121 Patient Start Forms submitted in first six weeks of launch.
- Cash, cash equivalents and investments $505.9M as of June 30, 2023.
- Net loss $33.2M ($1.25 per share) vs $28.1M ($1.10 per share) in Q2 2022.
- First CF patient dosed with KB407 in Phase 1 trial; KB707 IND accepted with Fast Track designation.
- Positive coverage from UnitedHealthcare and other national/regional health plans for VYJUVEK.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000067/0001711279-23-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000067/krys-20230807.htm
  HTML page:      https://secwatch.observer/filing/0001711279-23-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer